FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time

Executive Summary

• The FDA Center for Veterinary Medicine granted Innocan Pharma a sponsor fee waiver for its LPT‑CBD product for the third consecutive year, indicating continued regulatory support.
• A blinded, crossover study in osteoarthritic dogs showed statistically significant pain reduction and overall well‑being improvements with LPT‑CBD versus placebo.
• The waiver underscores the company’s innovation‑driven animal health program and supports its strategy to bring a once‑monthly subcutaneous analgesic for chronic canine pain to market.

Key Details

• Fee Waiver: FDA CVM sponsor fee waiver approved for 2026 – third consecutive annual waiver.
• Product Focus: LPT‑CBD (Liposome Platform Technology‑Cannabidiol) – subcutaneous injection targeting chronic pain in dogs.
• Clinical Evidence:
• Blinded, crossover trial in osteoarthritic dogs demonstrated statistically significant reduction in pain and meaningful improvements in overall well‑being versus placebo (empty liposomes).
• Reference: Shilo‑Benjamini et al., “Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs,” Front. Vet. Sci., 19 Jan 2026.
• Market Context: U.S. pet ownership estimated at 94 million households (2025 APPA report), indicating strong demand for safe, effective chronic pain solutions.
• Regulatory Significance: The waiver is granted under the “significant barrier to innovation” provision, reflecting FDA recognition of Innocan’s innovative animal‑health program.
• Future Plans Mentioned: Ongoing development toward human trials and continued regulatory submissions (forward‑looking statements).

Notable Quotes

“The veterinary market is open to new drug technologies that can address the limitations of current pain medications and offer a new alternative therapy,” – Dr. Antonio Benitz, Animal Health Advisor, Innocan.

“U.S. pet ownership continues to grow, with an estimated 94 million households owning at least one pet… Our technology is designed to meet rising demand for safe, effective chronic pain solutions, combining demonstrated therapeutic potential with the convenience of a single, once‑monthly administration,” – Dr. Eyal Kalo, Vice President of Research and Development, Innocan.